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Abstract
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As a canalicular bile acid effluxer, bile salt export pump (BSEP) plays a vital role in maintaining
bile acid homeostasis. BSEP deficiency leads to severe cholestasis and hepatocellular carcinoma
(HCC) in young children. Regardless of the etiology, chronic inflammation is the common
pathological process for HCC development. Clinical studies showed that bile acid homeostasis is
disrupted in HCC patients with elevated serum bile acid level as a proposed marker for HCC.
However, the underlying mechanisms remain largely unknown. In this study, we found that BSEP
expression was severely diminished in HCC tissues and markedly reduced in adjacent non-tumor
tissues. In contrast to mouse, human BSEP was regulated by farnesoid x receptor (FXR) in an
isoform-dependent manner. FXRα2 exhibited a much more potent activity than FXRα1 in
transactivating human BSEP in vitro and in vivo. The decreased BSEP expression in HCC was
associated with altered relative expression of FXRα1 and FXRα2. The FXRα1/FXRα2 ratios
were significantly increased with undetectable FXRα2 expression in one third of the HCC tumor
samples. Similar correlation between BSEP and FXR isoform expression was confirmed in
hepatoma Huh 7 and HepG2 cells. Further studies showed that intrahepatic proinflammatory
cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were significantly
elevated in HCC tissues. Treatment of Huh 7 cells with IL-6 and TNF-α resulted in a marked
increase in the FXRα1/FXRα2 ratio concurrent with a significant decrease in BSEP expression. In
conclusion, BSEP expression was severely diminished in HCC patients associated with alteration
of FXR isoform expression induced by inflammation, and the restoration of BSEP expression
through suppressing inflammation in the liver may re-establish the bile acid homeostasis.
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INTRODUCTION
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Bile acid homeostasis is achieved through a tightly regulated enterohepatic circulation, the
rate-limiting step of which is canalicular secretion of bile acids through bile salt export
pump (BSEP, ABCB11) (1, 2). Modulation of BSEP expression or function by inherited or
acquired factors has a profound impact on bile acid homeostasis. The expression of BSEP is
coordinately regulated by multiple transactivation pathways (3–7), notably the bile acid/
farnesoid x receptor (FXR, NR1H4) signaling pathway (3, 4). Activation of FXR by bile
acids strongly induces BSEP expression in vitro and in vivo (3, 4). Such feed-forward
regulation of BSEP by FXR is considered a major mechanism for preventing excessive
accumulation of toxic bile acids in hepatocytes. Two FXR genes, FXRα and FXRβ, have
been identified (8–10). FXRα is functional in all species tested while FXRβ is a pseudogene
in humans (10). Alternative promoter and splicing result in four isoforms of FXRα
(FXRα1–4) (11, 12) with predominant expression of FXRα1 and FXRα2 in human liver
(11). Currently, the pathophysiological significance of FXR isoform-specific regulation
remains unknown.

NIH-PA Author Manuscript

Maintenance of bile acid homeostasis is vital for health and disruption of bile acid balance is
associated with various diseases. Many pieces of evidence support a role of excessive
intrahepatic bile acids in the development of hepatocellular carcinoma (HCC). Children with
a deficiency in BSEP develop severe cholestasis and HCC at early ages (13, 14). Certain
genetic variations in BSEP are associated with susceptibility to develop HCC (15). FXR
knockout mice (FXR−/−) with dysregulation of BSEP spontaneously developed HCC as
they aged (16, 17). It is generally accepted that chronic exposure of hepatocytes to high
levels of bile acids contributes to liver tumor development. Indeed, feeding FXR(−/−) mice
with a diet containing bile acid strongly promoted N-nitrosodiethylamine-initiated liver
tumorigenesis, whereas lowering bile acid pool with a bile acid sequestrant considerably
reduced the malignant lesions (16). Thus disruption of bile acid homeostasis due to
impairments in BSEP expression may contribute to the pathogenesis of HCC.
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HCC is the most common primary liver cancer and one of the leading causes for cancerrelated deaths globally. The etiology of HCC mainly includes viral hepatitis (18, 19),
alcoholic and nonalcoholic fatty liver disease (20–22), and metabolic syndromes (23, 24).
Regardless of the etiology, the common pathological process for HCC development is
chronic liver injury and inflammation (25, 26). Clinical studies showed that bile acid levels
in serum and urine were significantly elevated with a concurrent decrease in fecal bile acids
in HCC patients (27–31), indicating disruption of bile acid homeostasis. Elevated serum bile
acid level has been proposed as a clinical marker for HCC (27–30). Currently, the
underlying mechanisms for bile acid imbalance in HCC patients are largely unknown.
In this study, we demonstrated that BSEP expression was dysregulated with altered FXR
isoform expression in HCC tissues and hepatoma cell lines Huh 7 and HepG2.
Transactivation studies in vitro and in vivo established that in contrast to mouse, human
BSEP was isoform-specifically regulated by FXR with FXRα2 being the predominant
regulator. Additional studies revealed that proinflammatory cytokines IL-6 and TNF-α
significantly elevated in HCC tissues and altered the FXRα1/FXRα2 ratio with concurrent
deceases in BSEP expression in Huh 7 cells. A potential link from inflammation to
disruption of bile acid homeostasis through alteration in the relative expression of FXR
isoforms and subsequent BSEP dysregulation was proposed in patients with HCC.
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MATERIALS AND METHODS
Reagents and suppliers
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Chemicals and reagents for polymerase-chain reaction (PCR), cell culture, transfection, and
luciferase assays were described previously (32). Recombinant human FXRα2, IL-1β, IL-6
and TNF-α were purchased from Pierce.
Liver samples
Fourteen healthy human liver samples and 22 HCC tumor (HCC-T) samples with 11 paired
adjacent non-tumor (HCC-NT) tissues were obtained from the University of Virginia,
University of Pennsylvania and Ohio State University through the Cooperative Human
Tissue Network (CHTN). The detailed information on HCC patients was provided in
Supplement Table 1 and 2. The protocol for using human tissues was approved by the
Institutional Review Board (IRB) at the University of Rhode Island (URI).
Plasmid constructs

NIH-PA Author Manuscript

Human and mouse BSEP promoter reporters, phBSEP(−2.6kb) and pmBSEP(−2.6kb), were
prepared as described previously (6, 32). Expression plasmids for human FXRα2 and
FXRα1 were provided by Dr. Matthew Stoner and Dr. David Mangelsdorf (University of
Texas Southwestern Medical Center).
Reporter luciferase assay
The reporter luciferase activity assays were carried out in Huh 7 cells in a 24-well plate
format and the luciferase activities were detected with a Dual-Luciferase Reporter Assay as
described (33).
Living imaging with in vivo imaging system (IVIS)
Eighteen CD-1 female mice were obtained from Charles River Laboratory and randomly
divided into three groups. Mice were injected with 5μg phBSEP(−2.6kb) and either 5μg
FXRα1, FXRα2 or pcDNA5 vector, respectively and subjected to IVIS 100 Living Imaging
detection with a exposure time of 45 seconds. The study was approved by the Institutional
Animal Care and Use Committees (IACUC) at URI.
Quantitative real-time PCR

NIH-PA Author Manuscript

Total RNA preparation from liver samples, Huh 7 and HepG2 cells, cDNA synthesis and
TaqMan real-time PCR were carried out as described (33). Transcript levels of FXR, BSEP,
IL-1β, IL-6 and TNFα were normalized against glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) levels.
Semi-quantification of FXRα1 and FXRα2 expression
A 600bp fragment encompassing the 12- nucleotides inserted in FXRα1 was amplified with
a sense primer 5′-TGTGGAGACAGAGCCTCTGGATACCACTATAATGC-3′ and an
antisense primer 5′-GAACATAGCTTCAACCGCAGACCCTTTCAGCAAG-3′. The PCR
products were equally divided into three tubes and completely digested with BstZ 17I, Bsm I
or buffer only, followed by separating the DNA fragments on 1.5% agarose gel and
quantified.
Cytokine treatment
Huh 7 cells were treated with 30ng/ml of IL-1β, IL-6 or TNFα in a medium containing 1%
dislipidated FBS (Invitrogen) for 48h. Total cellular RNA was extracted and cDNA was
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synthesized, followed by quantification of total FXR, FXRα1, FXRα2 and BSEP
expression.
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Western blotting
Crude membrane fractions from liver tissues were prepared as described (34). Membrane
fractions containing 25μg of total proteins were loaded into each well. After transfer, the
membrane was split with the top portion blotted for BSEP (~175kD) with an anti-human
BSEP mAb (sc- 74500, Santa Cruz Biotechnologies) and the bottom portion blotted for
GAPDH (35kD) with the rabbit anti-human GAPDH polyclonal antibodies (G9545, SigmaAldrich). FXR detection in FXRα1 or FXRα2-transfected cells or mouse livers was
performed using mouse anti-human FXR mAb (H00009971-M02, Abnova). The expression
levels of GAPDH were used to normalize BSEP or FXR expression.
Two-dimension electrophoresis followed by Western blot (2DWB)
Nuclear extracts from human liver tissues and HepG2 cells were used to detect FXRα1 and
FXRα2 according to the protocol provided in Supplement Fig. 1.
Mass spectrometry (MS)

NIH-PA Author Manuscript

Nuclear extracts from human liver tissues and HepG2 cells were applied to MS to detect
FXRα1 and FXRα2 protein. The detailed protocol was provided in the Supplement Fig. 2.
Statistic analysis
Student t-test was applied to pair-wise comparison for normally distributed data. Nonparametric Mann-Whitney test was used for pair-wise comparison for non-normally
distributed data. P value of 0.05 or lower was considered statistically significant.

RESULTS
BSEP expression was dramatically decreased in HCC tissues

NIH-PA Author Manuscript

Previous studies showed that bile acid levels increased in the serum and urine and decreased
in fecal excretion in HCC patients (27–31). We therefore hypothesized that BSEP
transcription was dysregulated in patients with HCC. To test the hypothesis, BSEP mRNA
levels were quantitatively determined in liver samples from HCC patients and healthy
subjects. As shown in Fig. 1A, when compared with healthy controls, the level of BSEP
mRNA was significantly reduced in both HCC tumor (HCC-T) and adjacent non-tumor
(HCC-NT) tissues. The median level of BSEP mRNA decreased by 72% and 97% in HCCNT (p=0.029) and HCC-T (p<0.001) samples, respectively. No statistical significance was
detected between HCC-NT and HCC-T (p=0.053). The data demonstrated that BSEP
transcription was severely dysregulated in HCC patients.
To determine whether the transcriptional dysregulation of BSEP in HCC patients correlates
with BSEP protein expression, Western blotting was performed to quantify BSEP protein in
all liver samples. As shown in Fig. 1B and 1C, compared with healthy subjects, BSEP
protein levels dramatically decreased in HCC-NT (p=0.001) and HCC-T (p<0.001) samples.
The median levels of expression decreased by 97% and 99% in HCC-NT and HCC-T
samples, respectively. Almost no BSEP protein was detected in any HCC-T samples. It was
thus concluded that BSEP expression severely diminished in HCC patients. It should be
noted that such diminished expression of BSEP did not result from decreased FXR
expression as no statistically significant changes in total FXR expression were detected
among the groups (Fig. 1D), suggesting other underlying mechanisms.
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Isoform-dependent transactivation of human BSEP by FXR in vitro
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FXRα1 and FXRα2 are predominant isoforms expressed in human liver (11). A previous
study showed that mouse ileal bile acid-binding protein was regulated differently by FXRα1
and FXRα2, while regulation of mouse BSEP by FXRα1 and FXRα2 displayed little
disparities (12). To determine whether human BSEP is transcriptionally regulated by FXR in
an isoform-specific manner, human BSEP promoter reporter, phBSEP(−2.6kb), was
cotransfected into Huh 7 cells with FXRα1 or FXRα2. Mouse BSEP promoter reporter,
pmBSEP(−2.6kb), was included in the experiments as a control. As shown in Fig. 2A,
FXRα2 exhibited over 20 fold higher activity than FXRα1 in transactivating human BSEP.
In contrast, FXRα1 and FXRα2 exhibited comparable activity with mouse BSEP (Fig. 2B).
It should be noted that the observed difference in human BSEP transactivation was not due
to the different levels of protein expression from the transfected FXR isoforms (Fig. 2C).
The data demonstrated that human BSEP was predominantly regulated by FXRα2.
Therefore, in addition to total FXR levels, the relative expression levels of FXRα1 and
FXRα2 should play an important role in determining human BSEP expression.

NIH-PA Author Manuscript

To demonstrate the effect of FXRα1/FXRα2 ratios on BSEP transactivation, a series of
FXRα1 and FXRα2 plasmid DNA in various ratios with a constant total amount of FXR
were co-transfected with human BSEP promoter reporter in Huh 7 cells. As shown in Fig.
2D, BSEP transactivation levels gradually decreased as FXRα1/FXRα2 ratios increased. It
was thus established that the FXRα1/FXRα2 ratio is a determinant in regulating human
BSEP expression.
Isoform-dependent transactivation of BSEP by FXR in vivo in mice
To further confirm the isoform-dependent regulation of human BSEP, we performed an in
vivo study in mice using IVIS 100 Living Imaging System. No signal was detected in mice
receiving pcDNA5 vector and phBSEP(−2.6kb), indicating that human BSEP transactivation
by endogenous mouse FXR is minimal (Fig. 3A). Detectable signals were readily captured
in mice co-injected with human FXRα1 and phBSEP(−2.6kb). Much more robust signals
were detected in mice co-injected with human FXRα2 and phBSEP(−2.6kb). Quantification
of the signals showed that FXRα2-induced human BSEP transactivation was 4.5 times
higher than FXRα1 on average (Fig. 3B) with similar levels of FXR protein expression in
mice injected with FXRα1 or FXRα2 (Fig. 3C). The data above concluded that human
BSEP was regulated by FXR in an isoform-dependent manner both in vitro and in vivo with
FXRα2 being the dominant regulator.
FXRα1/FXRα2 ratios were significantly altered in HCC tissues

NIH-PA Author Manuscript

After demonstrating the isoform-dependent regulation of human BSEP, we investigated
whether alteration in relative expression of FXRα1 and FXRα2 is a potential mechanism for
BSEP dysregulation in patients with HCC.
Digestion with restriction enzymes BstZ 17I and Bsm I differentiates the two FXR isoforms
(Fig. 4A). The PCR products derived from FXRα1 plasmid templates were completely
digested by BstZ 17I, whereas no digestion was observed with Bsm I (Fig. 4B). On the other
hand, Bsm I could completely digest the PCR products derived from the FXRα2 plasmid
templates, while no digestion was detected with BstZ 17I. In liver samples, the PCR
products resistant to either Bsm I or BstZ 17I digestion represent the relative amount of
FXRα1 and FXRα2 (Fig. 4B). In healthy subjects, FXRα1 was expressed more abundantly
than FXRα2 with a median FXRα1/FXRα2 ratio of 1.4 (Fig. 4C), and such ratio
significantly increased to 2.1 (p=0.001) in HCC-NT and 2.8 (p=0.002) in HCC-T samples.
More strikingly, the expression of FXRα2 was undetectable in 7 of the 22 HCC-T samples
and was therefore not included in Fig. 4C and statistical analysis. The data established that
Hepatology. Author manuscript; available in PMC 2014 April 01.
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the FXRα1/FXRα2 ratios varied greatly in patients with HCC and that such alteration
occurred in both tumor and adjacent non-tumor tissues.
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BSEP expression correlated with FXR isoform expression in hepatoma Huh 7 and HepG2
cells
To investigate whether BSEP expression in hepatoma cell lines correlates with FXR isoform
expression as revealed in HCC tissues, BSEP and FXR isoform expression levels were
quantified in Huh 7 and HepG2 cells. As shown in Fig. 5A, BSEP transcripts were readily
detected in Huh7 cells although at a decreased level when compared with healthy liver
samples. However, BSEP mRNA was undetectable in HepG2 cells. It should be noted that
such differences in BSEP transcription was not caused by the variation of total FXR
expression because there was no statistical difference in total FXR expression between the
two cell lines (Fig. 5B). Detection of FXR isoforms revealed that both FXRα1 and FXRα2
were expressed with an FXRα1/FXRα2 ratio of 1.72 in Huh 7 cells. In contrast, no FXRα2
expression was detected in HepG2 cells (Fig. 5C). The results indicated that Huh 7 cells
behaved similarly to most of the HCC tissues with increased FXRα1/FXRα2 ratio and
decreased BSEP expression while HepG2 cells behaved as the 7 HCC-T samples with no
detectable FXRα2 and completely diminished BSEP expression. The data thus confirmed
the phenomenon observed in HCC tissues.
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To further solidify the findings and determine whether supplying exogenous FXRα2 to
HepG2 cells can restore the expression of endogenous BSEP, HepG2 cells were transiently
transfected with increasing amounts of FXRα2, followed by quantification of BSEP mRNA.
As shown in Fig. 5D, transfection of exogenous FXRα2 indeed resulted in endogenous
BSEP expression in an FXRα2 dose-dependent manner. The data strongly supported the
notion that undetectable BSEP expression in HepG2 cells was due to the absence of FXRα2.
Alteration of FXR isoform protein expression in HCC and HepG2 cells

NIH-PA Author Manuscript

To determine whether the data on FXR isoform expression at mRNA level correlate with
their expression at protein levels, FXRα1 and FXRα2-specific proteins were detected by
2DWB and MS in representative liver tissues and HepG2 cells. Since HepG2 cells only
expressed FXRα1 at mRNA level, the respective FXRα1 and FXRα2 proteins were
detected by 2DWB with nuclear extracts from untransfected and FXRα2-transfected HepG2
cells (Supplement Fig. 1). In the healthy tissue, FXRα2 was dominantly expressed while a
new form of FXR protein started to appear in the HCC-NT sample. More significantly,
FXRα1 and the new form FXR protein were significantly increased in HCC-T samples
(Spplement Fig. 1). The relative expression of FXRα1 was increased from 11% in healthy
tissue to 59% of total FXR in HCC-T samples (Table 1). In the detection of FXRα1 and
FXRα2 protein by MS, the fingerprints of two signature peptides (FXRα1;
EMGMLAECMYTGLLTEIQCK and FXRα2: EMGMLAECLLTEIQCK) were shown in
Supplement Fig. 2. The relevant mass spectral abundance of the precursor ions of the two
signature peptides provided relative levels of the two proteins in the samples. Consistent
with the data from 2DWB, relative FXRα1 expression was markedly increased from 9% in
healthy tissue to 85% of total FXR in HCC-T samples (Table 1). Taken together, the data
demonstrated that the relative expression of the two FXR isoforms was significantly altered
in HCC. Such alteration may represent a mechanism for BSEP dysregulation in HCC
patients.
Proinflammatory cytokines IL-6 and TNF-α increased FXRα1/FXRα2 ratios with concurrent
decreases in BSEP expression
It is well established that chronic liver injury and inflammation are the common pathological
processes leading to HCC development (25, 26). To determine whether inflammation plays
Hepatology. Author manuscript; available in PMC 2014 April 01.
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a role in altering relative expression of FXRα1 and FXRα2, we treated Huh 7 cells with
IL-1β, IL-6 and TNF-α, followed by determination of FXRα1/FXRα2 ratios and BSEP
expression. As shown in Fig. 6A, treatment with IL-6 and TNF-α significantly shifted the
relative expression of FXRα1 and FXRα2. The FXRα1/FXRα2 ratios increased as much as
2.5 fold in cells treated with IL-6 (p=0.015) or TNF-α (p=0.003), while IL-1β had no
detectable effects (p=0.61). As expected, alteration in FXRα1/FXRα2 ratios corresponded
with BSEP expression (Fig. 6B), which decreased by 59% (p<0.001) and 31% (p=0.036) in
cells treated by IL-6 and TNF-α, respectively. On the contrary, treatment with IL-1β
resulted in a 30% increase in BSEP expression with no statistical significance (p=0.15).
Treatment with IL-6 (p=0.6), TNF-α (p=0.83), or IL-1β (p=0.17) induced unnoticeable
alteration in total FXR expression (Fig. 6C). In summary, IL-6 and TNF-α, but not IL-1β,
substantially increased FXRα1/FXRα2 ratio and decreased BSEP expression.
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Previous studies have shown that serum IL-6 and TNF-α concentrations were increased in
HCC patients (35, 36). Based on our finding, we propose that the levels of proinflammatory
cytokines IL-6 and TNF-α would be elevated in HCC tissues. Indeed, as shown in Fig. 7,
IL-6, TNF-α and IL-1β mRNA levels were greatly elevated in HCC-NT and HCC-T
samples when compared with healthy controls. The median IL-6 mRNA levels increased by
13.2 fold in HCC-NT (p<0.001) and 24.2 fold in HCC-T (p<0.001) samples, while the
median TNF-α mRNA level increased by 4.5 fold in HCC-NT (p=0.017) and 4.8 fold in
HCC-T (p<0.001) samples. Significant elevation of IL-1β mRNA levels were also detected
in HCC-NT (p=0.019) and HCC-T (p<0.001). The data revealed that the expression levels of
proinflammatory cytokines IL-6, TNF-α and IL-1β significantly elevated in HCC tissues.

DISCUSSION
As the canalicular effluxer of bile acids, BSEP has a direct impact on the enterohepatic
circulation of bile acids. In this study, we showed that BSEP expression was severely
diminished in both HCC and tumor-surrounding tissues, suggesting a reduced biliary
secretion of bile acids and accumulation of bile acids in the liver and body. The finding was
in agreement with the clinical measurements of bile acids in HCC patients (27–30). In one
study, total serum bile acid levels increased 5.7 fold in HCC patients (30). In another study,
serum glycochenodeoxycholic acid and taurocholic acid elevated 6.7 and 25.4 fold,
respectively while glycocholic acid levels increased 6.4 fold in serum and 45 fold in urine in
HCC patients (28). On the other hand, fecal metabolome profiling revealed that bile acids
dramatically decreased in HCC patients (31). Therefore, it was concluded that dysregulation
of BSEP was at least one of the mechanisms leading to the disruption of bile acid
homeostasis in HCC patients.
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FXRα1 and FXRα2 are the two predominant FXR isoforms in the human liver (11) with
isoforms FXRα3 and FXRα4 being undetectable (data not shown). A previous study
showed that mouse BSEP was comparably transactivated by FXRα1 and FXRα2 (12). In
contrast, we found that human BSEP was differentially regulated by FXRα1 and FXRα2
with FXRα2 being the predominant regulator in vitro and in vivo. Such species-specific
regulation of BSEP is not uncommon (6). Currently, the mechanisms for isoform-dependent
and species-specific regulation of BSEP by FXR are under investigation.
Similar to human BSEP, other FXR target genes including ileal bile acid-binding protein
(12), syndecan-1 (37) and fibrinogens (38) also exhibited isoform-specific regulation by
FXR. However, at present, its physiological and/or pathological significance are unknown.
In this study, we demonstrated that FXRα1 and FXRα2 expression was significantly altered
in HCC tissues in association with a marked reduction of BSEP expression. Such
observation in HCC tissues was fully in agreement with the data from hepatoma cell lines
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Huh 7 and HepG2 cells. We thus concluded that alteration in relative expression of FXR
isoforms may represent an underlying mechanism for BSEP dysregulation in HCC patients.
However, it remains to be determined whether other mechanisms such as epigenetic
modifications and alteration in coregulator recruitment, which occur commonly in
tumorigenesis, also indirectly contribute to BSEP dysregulation in HCC.
In the 2DWB, a new form of FXR protein appeared (Supplement Fig. 1) in HCC-NT and
HCC-T samples but absent in healthy tissue. It remains to be determined whether it is a
modified FXRα1, FXRα2 or a new isoform of FXR. Comparison of the data at mRNA and
protein levels, it was noted that FXRα1 was more abundantly expressed at the mRNA levels
while FXRα2 expression was predominantly expressed at the protein level in the same
healthy tissue. Similarly, FXRα2 mRNA levels were undetectable while FXRα2 proteins
were detected by both 2DWB and MS in the representative HCC-T samples. Such
discrepancy may indicate different post-transcriptional regulations of the two isoforms.
Additional studies are required to provide a full explanation for the phenomenon.
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Chronic inflammation is the hallmark for the development of HCC (25, 26). Consistently,
serum IL-6 and TNF-α concentrations significantly increased in HCC patients (35, 36) and
mouse model (39). There are also studies demonstrating that IL-6 and TNF-α play an
etiological role in the development of HCC (39, 40). Alternative splicing from a single
promoter results in FXRα1 and FXRα2 (11, 12). In this study, we found that IL-6 and TNFα but not IL-1β markedly altered relative expression of FXRα1 and FXRα2 with a
concurrent decrease in BSEP expression (Fig. 6A and 6B), indicating a possible crosstalk
between the FXR alternative splicing process and IL-6 and TNF-α signaling pathways.
Further studies are required to establish and reveal the mechanistic insights of such
crosstalk. The fact that in contrast to IL-6 and TNF-α, IL-1β had no significant effects on
FXR isoforms and BSEP expression (Fig. 6A and 6B) indicates that not general but
cytokine-specific chronic inflammation leads to alteration of FXR isoform and subsequently
BSEP expression.
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In comparison with healthy liver samples, adjacent HCC-NT tissues exhibited a significant
decrease in BSEP expression although at the levels not as severe as in HCC-T (Fig. 1),
indicating that BSEP dysregulation is not limited to the tumor but extended to adjacent liver
tissues. Similarly, the expression levels of proinflammatory cytokines IL-6, TNF-α and
IL-1β were markedly elevated in HCC-NT tissues at comparable levels to that in HCC-T
(Fig. 7). The data are in agreement with the notion that chronic inflammation leads to
decreased BSEP expression and tumorigenesis may further worsen BSEP dysregulation.
However, it remains to be determined whether such elevation in proinflammatory cytokine
levels and BSEP dysregulation extends to the entire liver.
Bile acids have been recognized as carcinogens and/or tumor promoters (41). Currently,
whether disruption of bile acid homeostasis is a trigger for initiating HCC development
remains to be established. However, a large body of evidence indicates that excessive bile
acids in the liver contribute to the pathogenesis of HCC (13, 14, 16, 17, 41–43). Indeed,
chronic exposure of hepatocytes to high levels of bile acids due to genetic defects in BSEP
in human (13, 14) or dysregulation of BSEP in FXR knockout mice (16, 17) do
spontaneously develop HCC. Bile acids are also implicated as etiological agents in colon
and esophagus cancer development (41–43). Based on our finding that BSEP expression was
severely diminished due to inflammation-mediated alteration of FXR isoform expression,
restoration of BSEP expression through controlling chronic inflammation in the liver may
re-establish the bile acid homeostasis, providing a possible approach for treatment and/or
prevention of HCC.
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BSEP

bile salt export pump

HCC

hepatocellular carcinoma

FXR

farnesoid X receptor

HCC-T

HCC tumor

HCC-NT

HCC non-tumor

IL-1β

interleukin-1beta

IL-6

interleukin-6

TNF-α

tumor necrosis factor-alpha

CDCA

chenodeoxycholic acid

DMSO

dimethyl sulfoxide

PCR, polymerase-chain
reaction. GAPDH

glyceraldehyde-3-phosphate dehydrogenase

IVIS

in vivo imaging system

CHTN

cooperative human tissue network. 2DWB, twodimension electrophoresis followed by Western blot

MS

Mass spectrometry
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Fig. 1. BSEP expression was markedly decreased in HCC tissues

(A) Expression levels of BSEP mRNA, (B, C) BSEP protein, and (D) total FXR mRNA in
healthy, HCC tumors (HCC-T) and paired adjacent non-tumor (HCC-NT) tissues. BSEP and
total FXR mRNA levels were quantified by TaqMan real-time PCR with GAPDH levels as
internal standards. BSEP protein levels were detected by Western blot and normalized with
GAPDH levels on the same blot. The median value of each group was indicated by a short
line. Non-parametric Mann-Whitney test was used for pair-wise comparison.

Hepatology. Author manuscript; available in PMC 2014 April 01.

Chen et al.

Page 14

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript
Hepatology. Author manuscript; available in PMC 2014 April 01.

Chen et al.

Page 15

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Fig. 2. Isoform-dependent transactivation of human BSEP by FXR in vitro

(A) FXRα1 and FXRα2-mediated transactivation of human BSEP promoter reporter
phBSEP(−2.6kb) and (B) mouse BSEP promoter reporter pmBSEP(−2.6kb) in the presence
of vehicle DMSO (0.1%) or CDCA (10μM). The data were presented as mean ± SD of at
least three separate experiments. Student’s t-test was applied to pairwise comparison. A
double asterisk (**) indicates p<0.001. (C). FXR protein levels were detected with Western
blot in FXRα1 or FXRα2-transfected cells. (D) The effects of FXRα1/FXRα2 ratios on
human BSEP transactivation.
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Fig. 3. Isoform-dependent transactivation of human BSEP by FXR in vivo in mice
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(A) Three groups of CD-1 female mice received human promoter reporter phBSEP(−2.6kb)
and either pcDNA5 vector, FXRα1 or FXRα2 expression plasmid DNA through
hydrodynamic tail vein injection. The transactivation levels were detected with IVIS Living
Imaging system. Two representative mice from each group were presented. (B)
Quantification of total signals (photons) in a fixed area covering the entire liver surface was
carried out with Living Imaging Software and presented as mean± SD. The asterisk (*)
indicates p<0.05 by the Student’s t-test. (C) FXR protein levels in the liver of FXRα1 or
FXRα2-injected mice were detected with Western blot.
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Fig. 4. FXRα1/FXRα2 ratios were significantly increased in HCC tissues

FXRα1 and FXRα2 differ by an insertion of 12 nucleotides in the hinge region in FXRα1
which is absent in FXRα2. A restriction enzyme site for BstZ 17I is located within the
inserted 12 nucleotides. Another restriction enzyme site for Bsm I is present in the junction
of the insertion in FXRα2 but destroyed by the insertion in FXRα1. Therefore, digestion
with BstZ 17I or Bsm I differentiates FXRα1 from FXRα2. (A) Sequence alignment of
FXRα1 and FXRα2 in the insertion junction. (B) Results from two representative healthy
liver samples and FXRα1 and FXRα2 plasmid controls were presented. PCR fragments
(600bp) containing the insertion junction were completely digested with BstZ 17I or Bsm I
generating two fragments with sizes of 400bp and 200bp. The intensity of the remaining
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600bp bands after digestion with BstZ 17I or Bsm I represented the expression levels of
FXRα2 or FXRα1. (C) FXRα1/FXRα2 ratios significantly increased in HCC-NT and
HCC-NT samples. The median value of each group was indicated by a short line. Nonparametric Mann-Whitney test was used for pair-wise comparison.
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Fig. 5. BSEP expression correlated with FXR isoform expression in Huh 7 and HepG2 cells

(A) Expression levels of BSEP mRNA and (B) total FXR mRNA were quantified by
TaqMan real-time PCR with GAPDH levels as internal standards. No BSEP mRNA
expression was detected in HepG2. (C) Expression of FXRα1 and FXRα2 in Huh 7 and
HepG2 cells. No FXRα2 expression was detected in HepG2 cells. (D) Exogenously
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transfected FXRα2 restored endogenous BSEP expression in a dose dependent manner in
HepG2 cells.
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Fig. 6. Proinflammatory cytokines IL-6 and TNF-α altered FXRα1/FXRα2 ratio and BSEP
expression

(A) Huh 7 cells were treated with proinflammatory cytokines IL-1β, IL-6 and TNF-α at a
concentration of 30ng/ml for 48h, followed by determination of FXRα1/FXRα2 ratios, (B)
BSEP and (C) total FXR mRNA levels. Student’s t-test was applied to pair-wise
comparison. A single asterisk (*) indicates p<0.05 and a double asterisk (**) indicates
p<0.001.
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Fig. 7. Proinflammatory cytokines IL-1β, IL-6 and TNF-α expression levels significantly
elevated in HCC tissues

(A) The expression levels of IL-6, (B) TNF-α and (C) IL-1β in healthy, HCC-T and HCCNT tissues were quantified by TaqMan real-time PCR with GAPDH levels as internal
standards. The median value of each group was indicated by a short line. Non-parametric
Mann-Whitney test was used for pairwise comparison.
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Table 1

Relative expression of FXRα1 at mRNA and protein levels
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FXR mRNA

FXR protein

Sample type

FXRα1 by RT-PCR (% of total FXR)

FXRα1 by MS (% of total FXR)

FXRα1 by 2DWB (% of total FXR)

Healthy

53

9

11

HCC-NT

71

10

7

HCC-T

100

85

59

HepG2

100

91

83
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